PURE Bioscience Net income (Q3, 2019)-1.9 M
PURE Bioscience EBIT (Q3, 2019)-912 K
PURE Bioscience Cash, 30-Apr-2019340 K

PURE Bioscience Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cost of goods sold

565.0k344.0k285.0k441.0k760.0k763.0k

R&D expense

1.3m1.0m790.0k927.0k779.0k459.0k

General and administrative expense

5.7m5.1m4.9m5.1m5.2m5.2m

Operating expense total

7.0m12.5m8.4m8.3m7.8m8.8m

EBIT

(7.3m)(11.9m)(7.6m)(7.1m)(6.0m)(7.0m)

Interest expense

593.0k10.0k8.0k10.0k5.0k8.0k

Net Income

(7.7m)(11.0m)(7.6m)(14.4m)(6.3m)(7.4m)

PURE Bioscience Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

32.0k86.0k1.3m5.2m1.6m851.0k

Accounts Receivable

18.0k47.0k189.0k263.0k297.0k275.0k

Inventories

249.0k207.0k350.0k273.0k197.0k

Current Assets

486.0k478.0k2.0m6.1m2.5m1.5m

PP&E

146.0k36.0k90.0k440.0k548.0k461.0k

Total Assets

2.1m1.9m3.3m7.6m3.8m2.6m

Accounts Payable

1.1m1.1m560.0k479.0k426.0k608.0k

Current Liabilities

2.2m1.8m869.0k2.5m2.5m1.3m

Total Liabilities

1.8m878.0k2.5m2.5m1.3m

Additional Paid-in Capital

69.1m80.9m90.8m107.6m110.1m117.5m

Retained Earnings

(70.2m)(81.2m)(88.8m)(103.2m)(109.5m)(116.9m)

Total Equity

(991.0k)17.0k2.4m5.0m1.3m1.3m

Financial Leverage

-2.1 x109.4 x1.4 x1.5 x3 x2 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

1.1m236.0k416.0k5.3m3.9m2.5m6.1m6.7m5.4m4.1m3.9m2.7m3.2m2.1m1.0m776.0k335.0k340.0k

Accounts Receivable

31.0k9.0k34.0k47.0k40.0k86.0k93.0k106.0k68.0k146.0k142.0k185.0k143.0k146.0k192.0k353.0k129.0k134.0k

Inventories

430.0k429.0k387.0k231.0k186.0k207.0k219.0k237.0k320.0k348.0k340.0k348.0k274.0k267.0k275.0k209.0k205.0k195.0k

Current Assets

1.8m895.0k1.0m5.8m4.2m2.9m6.6m7.2m6.2m5.0m4.6m3.5m3.9m2.7m1.6m1.5m793.0k772.0k

PP&E

127.0k115.0k42.0k28.0k90.0k97.0k83.0k231.0k407.0k495.0k568.0k574.0k530.0k515.0k487.0k443.0k416.0k388.0k

Total Assets

3.3m2.4m2.5m7.1m5.6m4.2m7.8m8.6m7.6m6.4m6.1m4.9m5.2m4.0m2.8m2.5m1.8m1.7m

Accounts Payable

771.0k629.0k529.0k510.0k510.0k533.0k384.0k582.0k522.0k654.0k424.0k574.0k425.0k449.0k486.0k420.0k525.0k386.0k

Current Liabilities

2.3m1.5m1.2m875.0k817.0k763.0k7.6m18.5m10.5m2.8m2.2m2.4m637.0k682.0k623.0k572.0k650.0k523.0k

Total Liabilities

3.1m1.5m1.2m887.0k7.6m18.5m10.5m2.8m2.2m2.4m647.0k699.0k638.0k584.0k660.0k530.0k

Additional Paid-in Capital

74.0m77.1m79.6m89.0m89.2m90.0m91.4m92.1m99.0m107.9m109.2m109.5m115.7m116.4m117.0m120.7m121.2m123.1m

Retained Earnings

(74.0m)(76.5m)(78.5m)(83.2m)(84.9m)(87.0m)(91.7m)(102.6m)(102.5m)(105.0m)(105.9m)(107.6m)(111.8m)(113.8m)(115.5m)(119.5m)(120.8m)(122.7m)

Total Equity

211.0k890.0k1.3m6.2m4.7m3.4m235.0k(9.9m)(2.9m)3.6m3.9m2.5m4.6m3.3m2.2m2.0m1.1m1.2m

Financial Leverage

15.6 x2.7 x1.9 x1.1 x1.2 x1.2 x33.3 x-0.9 x-2.6 x1.8 x1.6 x2 x1.1 x1.2 x1.3 x1.3 x1.6 x1.4 x

PURE Bioscience Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(7.7m)(11.0m)(7.6m)(14.4m)(6.3m)(7.4m)

Depreciation and Amortization

311.0k248.0k206.0k219.0k276.0k285.0k

Accounts Receivable

82.0k(29.0k)(142.0k)(74.0k)(34.0k)22.0k

Inventories

149.0k(12.0k)42.0k(143.0k)27.0k37.0k

Accounts Payable

(96.0k)(955.0k)(131.0k)(59.0k)103.0k

Cash From Operating Activities

(3.9m)(6.3m)(6.1m)(5.0m)(4.6m)(3.9m)

Purchases of PP&E

(12.0k)(21.0k)(81.0k)(390.0k)(206.0k)(19.0k)

Cash From Investing Activities

(231.0k)(46.0k)(107.0k)(405.0k)(226.0k)(34.0k)

Cash From Financing Activities

3.3m6.4m7.4m9.3m1.2m3.1m

Income Taxes Paid

1.6k4.0k1.6k2.0k7.0k3.0k

PURE Bioscience Ratios

USDY, 2019

Financial Leverage

1.4 x